Assignee
LEGEND BIOTECH USA INC
US·4 granted patents·7 pending applications·32 citations·filing 2016–2025
Top patents by PatentIndex Score
11 records- 0194US10934363B2Chimeric antigen receptors based on single domain antibodies and methods of use thereofLEGEND BIOTECH USA INC·Filed 2016·Granted Mar 2, 2021·24 cites·24 claims
- 0293US11186647B2Chimeric antigen receptors targeting BCMA and methods of use thereofLEGEND BIOTECH USA INC·Filed 2021·Granted Nov 30, 2021·4 cites·21 claims
- 0388US12351638B2Chimeric antigen receptors targeting BCMA and methods of use thereofLEGEND BIOTECH USA INC·Filed 2021·Granted Jul 8, 2025·1 cites·8 claims
- 0485US11535677B2Chimeric antigen receptors targeting BCMA and methods of use thereofLEGEND BIOTECH USA INC·Filed 2017·Granted Dec 27, 2022·3 cites·26 claims
- 0582US2024409654A1Chimeric antigen receptors targeting bcma and methods of use thereofLEGEND BIOTECH USA INC·Filed 2024·Application pending·0 cites
- 0669US2025000977A1Bcma-targeted car-t cell therapy for multiple myelomaLEGEND BIOTECH USA INC·Filed 2024·Application pending·0 cites
- 0768US2024358754A1Bcma-targeted car-t cell therapy for multiple myelomaLEGEND BIOTECH USA INC·Filed 2024·Application pending·0 cites
- 0859US2021261675A1Chimeric antigen receptors based on single-domain antibodies and methods of use thereofLEGEND BIOTECH USA INC·Filed 2021·Application pending·0 cites
- 0944US2024156962A1Bcma-targeted car-t cell therapy of multiple myelomaLEGEND BIOTECH USA INC·Filed 2023·Application pending·0 cites
- 1041US2025339527A1Bcma-targeted car-t cell therapy for multiple myelomaLEGEND BIOTECH USA INC·Filed 2025·Application pending·0 cites
- 1133US2025269024A1Bcma-targeted car-t cell therapy for multiple myelomaLEGEND BIOTECH USA INC·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when LEGEND BIOTECH USA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →